This report contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Companys judgment as of the date of this report. These forward-looking statements include, without limitation, statements regarding the Companys plans with respect to share repurchases. Actual events or results may differ from the Companys expectations. For example, the share repurchase program may be suspended or discontinued at any time. The failure to meet expectations with respect to any of the foregoing matters may reduce the Company's stock price. Additional information concerning these and other risk factors affecting the Company can be found in the Companys public periodic filings with the Securities and Exchange Commission available a t www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this report. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LIGAND PHARMACEUTICALS INCORPORATED
Date: September 24, 2018
/s/ Charles Berkman
Name: Charles Berkman
Title: Senior Vice President, General Counsel and Secretary
makes a similar move, sign up!
Other recent filings from the company include the following:
Ligand Pharmaceuticals Incorporated's Chief Executive Officer just picked up 4,315 shares - July 9, 2020
SVP of Ligand Pharmaceuticals Incorporated just picked up 238 shares - July 1, 2020
EVP of Ligand Pharmaceuticals Incorporated just picked up 238 shares - July 1, 2020